LiglimetTM

Linagliptin and Metformin Hydrochloride
DPP-4 Inhibitor's combination (Antidiabetic)

Indication:
LiglimetTM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin is appropriate.

Dosage & Administration:
Dose of this combination should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 2.5 mg Linagliptin and 1000 mg Metformin twice daily.
Linagliptin/Metformin combination should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to Metformin.
The recommended starting dose in patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin/500 mg Metformin Hydrochloride twice daily.

The recommended starting dose in patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin taken at each of the two daily meals.

The starting dose in Patients already treated with Linagliptin and Metformin individual components may be switched to Liglimet containing the same doses of each component.

Preparation:
LiglimetTM 2.5/500: Each box contains 18’s tablets in blister pack.
LiglimetTM 2.5/850: Each box contains 18’s tablets in blister pack.



  • Products By Trade Name

  • Products By Generic

  • Products By Therapeutic Class

  • Herbal & Nutraceuticals

  • AgroVet & Pesticides